Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · New England Journal of Medicine · 2016
BACKGROUND: On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a dose of 10 mg per kilogram in patients who had undergone complete resection of stage III melanoma. METHODS: After patients had undergone complete resection of stage III cutaneous melanoma, we randomly assigned them to receive ipilimumab at a dose of 10 mg per kilogram (475 patients) or placebo (476) every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred. Recurrence-free survival was the primary end point. Secondary end points included overall survival, distant metastasis-free survival, and safety. RESULTS: At a median follow-up of 5.3 years, the 5-year rate of recurrence-free survival was 40.8% in the ipilimumab group, as compared with 30.3% in the placebo group (hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). The rate of overall survival at 5 years was 65.4% in the ipilimumab group, as compared with 54.4% in the placebo group (hazard ratio for death, 0.72; 95.1% CI, 0.58 to 0.88; P=0.001). The rate of distant metastasis-free survival at 5 years was 48.3% in the ipilimumab group, as compared with 38.9% in the placebo group (hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P=0.002). Adverse events of grade 3 or 4 occurred in 54.1% of the patients in the ipilimumab group and in 26.2% of those in the placebo group. Immune-related adverse events of grade 3 or 4 occurred in 41.6% of the patients in the ipilimumab group and in 2.7% of those in the placebo group. In the ipilimumab group, 5 patients (1.1%) died owing to immune-related adverse events. CONCLUSIONS: As adjuvant therapy for high-risk stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis-free survival than placebo. There were more immune-related adverse events with ipilimumab than with placebo. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00636168 , and EudraCT number, 2007-001974-10 .).
Cited by 1,318 works. doi:10.1056/nejmoa1611299 Open-access PDF
Authors
- Alexander M.M. Eggermont
- Vanna Chiarion‐Sileni
- Jean‐Jacques Grob
- Reinhard Dummer
- Jedd D. Wolchok
- Henrik Schmidt
- Omid Hamid
- Caroline Robert
- Paolo A. Ascierto
- Jon M. Richards
- Célèste Lebbé
- Virginia Ferraresi
- Michael Smylie
- Jeffrey S. Weber
- Michele Maio
- Lars Bastholt
- Laurent Mortier
- Luc Thomas
- Saad Tahir
- Axel Hauschild
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
- Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases